 |
|
|
| |
Pharmacokinetics (PK) and Safety of Dolutegravir (DTG) in Subjects With Severe Renal Impairment and Healthy Controls
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
Stephen Weller,1 Julie Borland,1 Shuguang Chen,1 Mark Johnson,1 Paul Savina,1 Brian Wynne,2 Stephen Piscitelli1
1-2GlaxoSmithKline, 1Research Triangle Park, NC, USA; 2Upper Providence, PA, USA
|
| |
|
|
|
|
|
